1,25-Dihydroxyvitamin D3-induced aortic calcifications in experimental uremia: up-regulation of osteoblast markers, calcium-transporting proteins and osterix

J Hypertens. 2011 Feb;29(2):339-48. doi: 10.1097/HJH.0b013e328340aa30.

Abstract

Background and objective: Whether treatment with vitamin D receptor activators contributes to cardiovascular disease in patients with chronic kidney disease is a matter of debate. We studied mechanisms involved in vitamin D-related vascular calcifications in vivo and in vitro.

Methods: Aortic calcifications were induced in subtotally nephrectomized (SNX) rats by treatment with a high dose (0.25 μg/kg per day) of 1,25-dihydroxyvitamin D3 (calcitriol) given for 6 weeks. Likewise, primary rat vascular smooth muscle cells (VSMCs) were incubated with calcitriol at concentrations ranging from 10 to 10 mol/l. Immunohistochemistry revealed that the aortic expression of osteopontin, osteocalcin and bone sialoprotein was significantly increased in calcitriol-treated SNX rats compared to untreated SNX controls. In addition, aortic expression of the transient receptor potential vanilloid calcium channel 6 (TRPV6) and calbindin D9k was significantly up-regulated by treatment with calcitriol. Furthermore, calcitriol significantly increased expression of the osteogenic transcription factor osterix. In-vitro studies showed similar results, confirming that these effects could be attributed to treatment with calcitriol.

Conclusions: High-dose calcitriol treatment induces an osteoblastic phenotype in VSMC both in SNX rats and in vitro, associated with up-regulation of proteins regulating mineralization and calcium transport, and of the osteogenic transcription factor osterix.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aortic Diseases / etiology*
  • Aortic Diseases / metabolism
  • Aortic Diseases / pathology
  • Base Sequence
  • Biomarkers / metabolism
  • Calbindins
  • Calcinosis / etiology*
  • Calcinosis / metabolism
  • Calcinosis / pathology
  • Calcitriol / administration & dosage
  • Calcitriol / adverse effects*
  • Calcium Channels / genetics
  • Calcium Channels / metabolism
  • Calcium-Binding Proteins / genetics
  • Calcium-Binding Proteins / metabolism
  • Cells, Cultured
  • Core Binding Factor Alpha 1 Subunit / genetics
  • Core Binding Factor Alpha 1 Subunit / metabolism
  • DNA Primers / genetics
  • Disease Models, Animal
  • Humans
  • Male
  • Myocytes, Smooth Muscle / drug effects
  • Myocytes, Smooth Muscle / metabolism
  • Nephrectomy
  • Osteoblasts / drug effects*
  • Osteoblasts / metabolism
  • Osteoblasts / pathology
  • Rats
  • Rats, Sprague-Dawley
  • S100 Calcium Binding Protein G / genetics
  • S100 Calcium Binding Protein G / metabolism
  • TRPV Cation Channels / genetics
  • TRPV Cation Channels / metabolism
  • Transcription Factors / genetics
  • Transcription Factors / metabolism
  • Up-Regulation / drug effects
  • Uremia / complications*
  • Uremia / metabolism
  • Uremia / pathology

Substances

  • Biomarkers
  • Calbindins
  • Calcium Channels
  • Calcium-Binding Proteins
  • Core Binding Factor Alpha 1 Subunit
  • DNA Primers
  • Runx2 protein, rat
  • S100 Calcium Binding Protein G
  • S100G protein, human
  • S100g protein, rat
  • Sp7 protein, rat
  • TRPV Cation Channels
  • TRPV5 protein, rat
  • TRPV6 channel
  • Transcription Factors
  • Calcitriol